Targets › CD28
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Sep 2029.
Receptor that plays a role in T-cell activation, proliferation, survival and the maintenance of immune homeostasis. Functions not only as an amplifier of TCR signals but delivers unique signals that control intracellular biochemical events that alter the gene expression program of T-cells. (UniProt, P10747)
Open in Phaseline: the race on CD28, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Vonsetamig (REGN5459) CD28 costimulation modulator bispecific antibody | CD28 | Phase 1 | Lupus Nephritis (LN) | Sep 2029 |
Lupus Nephritis (LN) (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.